Physician profile

Cody S Osborn

Physician Assistant · Monterey, CA

NPI 1669061297

$903.52

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$542.11

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Journey Medical Corporation $222.59 2023
Abbvie INC. $201.26 2022-2023
Janssen Biotech, INC. $122.78 2023-2024 Tremfya
Genzyme Corporation $108.46 2022-2023
Ucb, INC. $98.72 2022-2023 Fintepla, Cimzia
Sun Pharmaceutical Industries INC. $47.00 2022
Lilly USA, LLC $37.20 2022
Novartis Pharmaceuticals Corporation $27.20 2022
Merz North America, INC. $25.40 2023 Xeomin
Amgen INC. $12.91 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Cody S Osborn

$903.52

in general payments reported 2019-2025

Years
2022-2024
Top company
Journey Medical Corporation

https://glasscript.com/doctor/11415421/cody-s-osborn

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.